Drugs / EPI-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06745973 | Dec 2024 → Dec 2026 expected | chronic hepatitis B virus infection | Epigenic Therapeutics, Inc | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06661148 | Dec 2024 → Jun 2027 expected | chronic hepatitis B virus infection | Epigenic Therapeutics, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPI-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06661148 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion.” NCT06661148 ↗ |